A sponsor-focused guide to clinical trials in Serbia; covering ALIMS regulation, recent reform momentum, compact site geography around Belgrade, strong investigator experience, and patient recruitment advantages.
Serbia has emerged as one of the most dynamic non-EU destinations for clinical trials in the Balkans. With experienced investigators, EU-aligned standards, compact site geography, and recent regulatory reforms, Serbia gives sponsors a practical route into high-quality Balkan research capacity.
Trials are regulated by ALIMS (Agencija za lekove i medicinska sredstva Srbije); the Medicines and Medical Devices Agency; which operates transparently with a public clinical trial database on the eGovernment portal. A landmark December 2024 reform package brought significant improvements: private healthcare institutions can now conduct Phase I trials (previously restricted to Phases II–III), import approval for investigational products is now issued simultaneously with trial approval, ALIMS formally takes EMA and ICH decisions into account when reviewing applications, and the prior clinical trial experience requirement for principal investigators was removed; broadening the investigator pool considerably.
Serbia's 6.7 million people are predominantly Serbian (83%), with Hungarian, Bosniak, Roma, and other minority communities adding demographic diversity. Approximately 56% of the population is urban, concentrated in Belgrade (1.7M) and secondary cities Novi Sad, Niš, and Kragujevac. The population skews toward the productive working age range (63% aged 15–64), and Serbia's high burden of cardiovascular disease, oncological conditions, and respiratory disease creates large, treatment-naïve patient pools that sponsors find highly attractive.
A key operational advantage: all clinical trial sites in Serbia are located within a 350 km radius of Belgrade; enabling extraordinarily efficient multi-site coordination, same-day investigator meetings, and rapid logistics that simply cannot be replicated in larger countries. Patient motivation to participate is high, partly because clinical trials offer access to novel biologics not yet covered under Serbia's state-funded healthcare programme.
The 350 km advantage: Every single clinical trial site in Serbia sits within a 350 km radius of Belgrade. For sponsors running multi-site programmes, monitoring visits, site meetings, and logistics that take days in larger countries can be completed in hours. Combined with Serbia's GMP certificate sufficiency (EU QP Statement not required), operational friction is notably lower than in many EU peers.
Serbia's appeal is the combination of EU-aligned regulatory standards without EU bureaucratic overhead, a deeply experienced investigator community (GCP-compliant multicentre trials were practiced in former Yugoslavia since the 1970s), high patient recruitment rates, and competitive costs. The December 2024 reforms removed several long-standing friction points, and ALIMS's integration of EMA reliance into its review process signals a clear direction toward further harmonization.
EU-aligned legislation without EU membership overhead; Dec 2024 reforms enable Phase I in private hospitals, simultaneous IMP import approval, and EMA reliance integrated into ALIMS review; ePortal submission; ALIMS WHO Listed Authority ambition; regulatory reliance pilot launched 2024.
Significantly lower costs than EU markets; GMP certificate sufficient (EU QP Statement not required); competitive investigator fees; state healthcare system driving patient motivation; 95% enrollment target achievement rate reported by major CROs operating in Serbia.
6.7M people with large cardiovascular, oncology, and pulmonary disease burden; high treatment-naïve populations; strong physician-patient trust driving over 90% participation willingness; all sites within 350 km of Belgrade enabling fast multi-site recruitment coordination.
Europe's largest clinical institution (KCS) with 50+ research installations and 3,150 beds; GCP tradition dating to the Yugoslav era (1970s); deep bench of experienced investigators; growing CRO ecosystem; Belgrade's excellent regional air connectivity.
Oncology leads Serbia's trial portfolio, supported by neurology and cardiology where treatment-naïve populations and experienced investigators deliver strong enrollment. Pulmonology rounds out the top four. Phase III dominates the phase distribution, consistent with Serbia's strength in late-stage commercial enrollment.
Belgrade dominates Serbian clinical research, home to the country's university hospital complexes and the renowned KCS (Clinical Centre of Serbia). Secondary hubs in Novi Sad, Niš, and Kragujevac provide regional coverage; all within the 350 km radius that makes Serbia operationally unique.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | Clinical Centre of Serbia (KCS) | Belgrade | Europe's largest clinical institution; 3,150 beds; 50+ research installations; University of Belgrade Medical Faculty affiliate; broad Phase II–IV across oncology, cardiology, neurology, and hematology; anchor site for the majority of Serbian commercial trials. |
| 02 | Institute for Oncology and Radiology of Serbia (IORS) | Belgrade | National oncology research institute; Phase II–IV solid tumour and hematologic malignancy trials; University of Belgrade affiliate; strong investigator-initiated and commercial oncology portfolio; major Phase III commercial site. |
| 03 | Institute of Cardiovascular Diseases Dedinje | Belgrade | National cardiovascular specialist institute; Phase II–IV cardiac trials; interventional cardiology and heart failure specialty; large treatment-naïve cardiovascular patient population; strong commercial Phase III portfolio. |
| 04 | Clinical Centre of Vojvodina | Novi Sad | Northern Serbia anchor; University of Novi Sad Medical Faculty affiliate; oncology, neurology, and endocrinology trials; access to Vojvodina's ethnically diverse population (Serbian, Hungarian, Slovak, Romani); Phase II–IV portfolio. |
| 05 | Institute of Neurology, Clinical Centre of Serbia | Belgrade | National neurology specialist; Phase II–IV CNS trials; multiple sclerosis, epilepsy, and neurodegenerative disease specialty; large treatment-naïve neurological patient pool; University of Belgrade affiliate. |
| 06 | University Children's Hospital Belgrade | Belgrade | Paediatric specialty hospital; paediatric oncology, rare disease, and infectious disease trials; Phase II–IV; University of Belgrade affiliate; access to Serbian paediatric patient population. |
| 07 | Clinical Centre Niš | Niš | Southern Serbia anchor; University of Niš Medical Faculty affiliate; oncology, cardiovascular, and pulmonology trials; access to Southern Serbia's patient population; Phase II–III commercial portfolio. |
| 08 | Institute for Pulmonary Diseases of Vojvodina | Sremska Kamenica | National pulmonology specialist; respiratory oncology and COPD/asthma trials; Phase II–IV; large treatment-naïve respiratory patient population; major commercial pulmonology portfolio. |
| 09 | Military Medical Academy (VMA) | Belgrade | Military academic hospital; oncology, cardiovascular, and endocrinology trials; GCP-trained investigator teams; efficient site management; access to military and civilian Belgrade patient populations; Phase II–IV. |
| 10 | Clinical Hospital Centre Bežanijska Kosa | Belgrade | Belgrade university hospital; internal medicine, nephrology, and oncology trials; Phase II–III; growing commercial research portfolio; large West Belgrade patient catchment. |
| 11 | Institute for Rheumatology | Belgrade | National rheumatology specialist; Phase II–IV rheumatology and autoimmune trials; large treatment-naïve rheumatoid arthritis, lupus, and SpA patient pools; strong commercial Phase III portfolio for biologics and JAK inhibitors. |
| 12 | Clinic for Hematology, Clinical Centre of Serbia | Belgrade | National hematology unit within KCS; Phase II–IV hematologic malignancy trials; bone marrow transplantation; CAR-T and bispecific antibody trials; University of Belgrade affiliate. |
Europe's largest clinical institution; 3,150 beds; 50+ research installations; University of Belgrade Medical Faculty affiliate; broad Phase II–IV across oncology, cardiology, neurology, and hematology; anchor site for the majority of Serbian commercial trials.
National oncology research institute; Phase II–IV solid tumour and hematologic malignancy trials; University of Belgrade affiliate; strong investigator-initiated and commercial oncology portfolio; major Phase III commercial site.
National cardiovascular specialist institute; Phase II–IV cardiac trials; interventional cardiology and heart failure specialty; large treatment-naïve cardiovascular patient population; strong commercial Phase III portfolio.
Northern Serbia anchor; University of Novi Sad Medical Faculty affiliate; oncology, neurology, and endocrinology trials; access to Vojvodina's ethnically diverse population (Serbian, Hungarian, Slovak, Romani); Phase II–IV portfolio.
National neurology specialist; Phase II–IV CNS trials; multiple sclerosis, epilepsy, and neurodegenerative disease specialty; large treatment-naïve neurological patient pool; University of Belgrade affiliate.
Paediatric specialty hospital; paediatric oncology, rare disease, and infectious disease trials; Phase II–IV; University of Belgrade affiliate; access to Serbian paediatric patient population.
Southern Serbia anchor; University of Niš Medical Faculty affiliate; oncology, cardiovascular, and pulmonology trials; access to Southern Serbia's patient population; Phase II–III commercial portfolio.
National pulmonology specialist; respiratory oncology and COPD/asthma trials; Phase II–IV; large treatment-naïve respiratory patient population; major commercial pulmonology portfolio.
Military academic hospital; oncology, cardiovascular, and endocrinology trials; GCP-trained investigator teams; efficient site management; access to military and civilian Belgrade patient populations; Phase II–IV.
Belgrade university hospital; internal medicine, nephrology, and oncology trials; Phase II–III; growing commercial research portfolio; large West Belgrade patient catchment.
National rheumatology specialist; Phase II–IV rheumatology and autoimmune trials; large treatment-naïve rheumatoid arthritis, lupus, and SpA patient pools; strong commercial Phase III portfolio for biologics and JAK inhibitors.
National hematology unit within KCS; Phase II–IV hematologic malignancy trials; bone marrow transplantation; CAR-T and bispecific antibody trials; University of Belgrade affiliate.
These are the primary regulatory, academic, and industry bodies shaping Serbia's clinical research ecosystem.
National regulatory authority; ePortal submission; public clinical trial database; Dec 2024 reforms enable Phase I private sites, simultaneous IMP import, and EMA reliance; WHO Listed Authority ambition; ALIMS publishes all approved trial information for transparency.
Ethics oversight; CEC review runs simultaneously with ALIMS regulatory review; site agreements can begin before study approval; centralized ethics pathway enabling efficient multi-site initiation.
Serbia's leading medical school; affiliates KCS, IORS, and major Belgrade hospitals; drives the investigator pipeline; GCP training programmes; long tradition of academic clinical research dating to the Yugoslav GCP era.
Major CRO with Serbian operations; 95% enrollment target achievement; regulatory and contracting management; Phase I–IV; rapidly growing portfolio across oncology, neurology, and cardiology.
Regional CEE CRO with Serbian coverage; oncology, cardiology, rare disease; site management across Belgrade and Vojvodina; links Serbian sites into CEE multi-country programmes.
Global CRO with Belgrade operations; ALIMS regulatory expertise; Phase II–IV management; national site network across KCS, IORS, and regional centres.
For sponsors evaluating clinical trials in Serbia, the opportunity is defined by the country's regulatory pathway, investigator depth, patient access, and fit within a wider regional clinical research strategy. This profile is designed to support faster country feasibility, smarter site selection, and more informed clinical trial planning through Kitsa.
Serbia is the Balkans' most sophisticated non-EU clinical research market; and the December 2024 reforms have addressed virtually every major friction point sponsors historically cited. All sites within 350 km of Belgrade, GMP certificate sufficient without EU QP Statement, a GCP tradition running back to the 1970s, Phase I now open to private hospitals, simultaneous IMP import approvals, and ALIMS formally integrating EMA decisions into its review process. With 452 trials launched since 2023 and oncology, neurology, cardiology, and pulmonology all showing strong enrollment, Serbia is a compelling addition to any CEE clinical programme; and an essential one for sponsors wanting Balkans patient populations or non-EU operational flexibility alongside EU-standard data quality.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.